Its loss was noticed in aggressive ovarian cancer types and recombinant SFRP4 (rSFRP4) treatment of serous ovarian cancer cells that result in the inactivation of the Wnt/β-catenin pathway, mesenchymal-to-epithelial transition, and decreasing ability to migrate (33). Here, SFRP4 is linked to ovarian serous adenocarcinoma.